Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma

Clinical Cancer Research

Volumn 8, Issue 2, 2002, Pages 383-393

  Bramwell, Vivien H C ^a   Morris, Donald ^b   Ernst, D Scott ^b   Hings, Ingrid ^c   Blackstein, Martin ^d   Venner, Peter M ^e   Ette, Ene I ^f   Harding, Matthew W ^f   Waxman, Allison ^g   Demetri, George D ^g  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

^b TOM BAKER CANCER CENTRE   (Canada)

^c MONTREAL GENERAL HOSPITAL   (Canada)

^d MOUNT SINAI HOSPITAL   (Canada)

^e CROSS CANCER INSTITUTE   (Canada)

^f VERTEX PHARMACEUTICALS   (United States)

^g Dana Farber Cancer Institute   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIRICODAR; COLONY STIMULATING FACTOR; CYTOCHROME P450; DOXORUBICIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CARDIOMYOPATHY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG RESISTANCE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; MALE; MAXIMUM TOLERATED DOSE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SOFT TISSUE SARCOMA; THORAX RADIOGRAPHY;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PIPERIDINES; PYRIDINES; SARCOMA; SOFT TISSUE NEOPLASMS; TIME FACTORS;

EID: 0036190730     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (96)

1. Cancer statistics 2000
2. NCCN sarcoma practice guidelines
3. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma
4. Soft-tissue sarcoma: Initial characteristics and prognostic factors in patients with and without metastatic disease
5. Chemotherapy for advanced sarcoma: Therapeutic decisions and modalities
6. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
7. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas
8. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. A meta-analysis and clinical practice guideline
9. An intergroup Phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas
10. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: An analysis of 2,185 patients treated with anthracycline-containing first-line regimens - A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study
11. Hepatic metastases from soft tissue sarcoma
12. Clinical and pathological characteristics of gastrointestinal stromal tumors (GIST)
13. Multidrug resistance: Molecular mechanisms and clinical relevance
14. Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance
15. P-glycoprotein - A mediator of multidrug resistance in tumour cells
16. Biology of the multidrug resistance protein, MRP
17. MDR1 gene expression: Evaluation of its use as a molecular marker for prognosis and chemotherapy of bone and soft tissue sarcomas
18. Expression of MDR1 and GST-π in human soft tissue sarcomas: Relation to drug resistance and biological aggressiveness
19. Expression of MDR1/P glycoprotein in human sarcomas
20. Reverse transcriptase-polymerase chain reaction amplification of MDR1 gene expression in adult soft tissue sarcomas
21. Expression of multidrug-resistance-associated protein gene in human soft-tissue sarcomas
22. 1and LRP expression in relation to treatment response and survival of adult sarcoma patients treated with epirubicin, vindesine and ifosfamide (EVI)
23. Multidrug resistance phenotype in high grade soft tissue sarcoma: Correlation of P-glycoprotein immunohistochemistry with pathologic response to chemotherapy
24. Incidence of P-glycoprotein overexpression and multidrug resistance (MDR) reversal in adult soft tissue sarcoma
25. P-glycoprotein expression in soft-tissue sarcomas
26. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin
27. Evaluation of newer prognostic markers for adult soft tissue sarcomas
28. Experimental reversal of P-glycoprotein-mediated multidrug resistance by pharmacological chemosensitisers
29. Clinical trials of P-glycoprotein reversal in solid tumours
30. Cellular and biochemical characterization of VX-710 as a chemosensitizer: Reversal of P-glycoprotein-mediated multidrug resistance in vitro
31. Chemosensitization and drug accumulation effects of VX-710, verapamil, cyclosporin A, MS-209 and GF120918 in multidrug resistant HL60/ADR cells expressing the multidrug resistance-associated protein MRP
32. Phase I and pharmacokinetic study of paclitaxel in combination with biricodar, a novel agent that reverses multidrug resistance conferred by overexpression of both MDR1 and MRP
33. BIRICODAR (VX-710: Incel): An effective chemosensitizer in neuroblastoma
34. Phase I and pharmacokinetic study of the novel MDR1 and MRP1 inhibitor biricodar administered alone and in combination with doxorubicin
35. Design of Phase II clinical trials incorporating response and early progression
36. Contrast of response to D-MAP + sargramostim between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas
37. Preliminary results of a two-arm Phase 2 trial of gemcitabine (GEM) in patients (pt) with gastrointestinal leiomyosarcomas (leio) and other soft tissue sarcoma (STS)
38. Ecteinascadin (ET 743) shows promising activity in distinct populations of sarcoma patients: Summary of 3 US-based Phase II trials
39. Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study
40. Pharmacokinetics and metabolism of epidoxorubicin and doxorubicin in humans
41. Clinical pharmacokinetics of doxorubicin
42. Investigations on the dose-dependent pharmacokinetics of Adriamycin and its metabolites
43. Risk factors for doxorubicin-induced congestive heart failure
44. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistance phenotype
45. Expression and activity of P-glycoprotein, a multidrug effiux pump, in human hematopoietic stem cells
46. Phase II study of the safety, pharmacokinetics and efficacy of Incel (Biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone refractory prostate cancer
47. High dose alkylation therapy using ifosfamide infusion with mesna in the treatment of adult advanced soft tissue sarcoma
48. Cyclophosphamide versus ifosfamide: Final report of a randomized Phase II trial in adult soft tissue sarcomas
49. Response to ifosfamide and mesna: 124 Previously treated patients with metastatic or unresectable sarcoma
50. Results of single agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic
51. High-dose ifosfamide: Circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas
52. High-dose ifosfamide in bone and soft tissue sarcomas: Results of Phase II and pilot studies - Dose-response and schedule dependence
53. Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: A study of the Spanish Group for Research on Sarcomas (GEIS)
54. Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre Phase II study of the EORTC soft tissue and one sarcoma group
55. Dose response evaluation of Adriamycin in human neoplasia
56. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized Phase II/Phase III Study of the EORTC Soft Tissue and Bone Sarcoma Group
57. High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC Soft Tissue and Bone Sarcoma Group
58. Carminomycin vs. Adriamycin in advanced soft tissue sarcomas: An EORTC randomized Phase II study
59. Aclacinomycin A: Phase II evaluation in advanced soft tissue sarcoma
60. Phase II study of mitoxantrone in untreated and previously minimally treated patients with metastatic soft tissue sarcomas
61. Phase II trials of tetrahydropyranyladriamycin (Pirarubicin) on renal and colon carcinoma, melanoma and soft tissue sarcoma
62. The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR)
63. Increased intracellular accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (PSC833) with sterically stabilized liposomal doxorubicin
64. In vitro accumulation and cytotoxicity of liposomal and conventional formulations of daunorubicin and doxorubicin in resistant K562 cells
65. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes
66. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: Results of a randomized Phase III clinical trial
67. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation
68. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer
69. A Phase II study of Doxil (liposomal doxorubicin): Lack of activity in poor prognosis soft tissue sarcomas
70. Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas
71. Early results of pegylated liposomal doxorubicin (Doxil) in refractory sarcoma
72. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcoma: A Phase II study of the Italian Sarcoma Group (ISG)
73. A randomized Phase II trial of Caelyx/Doxil versus doxorubicin in advanced or metastatic soft tissue sarcoma (STS): An EORTC Soft Tissue and Bone Sarcoma Group (STBSG) trial
74. Phase II study with Taxotere (RP56976) in advanced soft tissue sarcomas of the adult
75. A Phase II study of docetaxel in chemotherapy-naive patients with recurrent or metastatic adult soft tissue sarcoma
76. Lack of activity of docetaxel in soft tissue sarcomas: Results of a Phase II study of the Italian Group on Rare Tumors
77. Randomized Phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
78. A Phase II trial of paclitaxel in patients with advanced soft tissue sarcomas
79. A Phase II trial of paclitaxel in the treatment of recurrent or metastatic soft tissue sarcomas or bone sarcomas
80. Phase II trial of paclitaxel in patients with soft tissue sarcoma
81. Phase II study of topotecan (NSC 609699) in patients with recurrent or metastatic soft tissue sarcoma
82. Phase II study of irinotecan (CPT-11) in relapsed or refractory soft tissue sarcoma (STS)
83. Phase II study of raltitrexed (Tomudex) for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens
84. Phase II study of temozolomide in advanced sarcomas
85. Limited activity and acceptable toxicity of gemcitabine in a Phase II study of patients with advanced sarcomas: A Mayo Cancer Center Study
86. Gemcitabine in soft tissue or bone sarcoma resistant to standard chemotherapy: A Phase II study
87. Esophageal stromal tumors: A clinicopathologic, immunohistochemical, and molecular genetic study of 17 cases and comparison with esophageal leiomyomas and leiomyosarcomas
88. CD117: A sensitive marker for gastrointestinal stromal tumors that is more specific than CD34
89. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
90. Mutations in exon 11 of c-kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas
91. Effect of tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor
92. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: Biological and clinical implications
93. Evaluation of the safety and efficacy of an oral molecularly targeted therapy, STI571, in patients (pts) with unresectable or metastatic gastrointestinal stromal tumors (GIST) expressing C-KIT (CD117)
94. STI571, an active drug in metastatic gastrointestinal stromal tumors (GIST), an EORTC Phase I study
95. The MDR-1 positive K562/dox cell line is resistant to the ABL tyrosine kinase inhibitor STI571